Media Articles Related to Folotyn (Pralatrexate)
Five-year survival data suggest brentuximab vedotin potentially curative in some hodgkin lymphoma patients with limited treatment options
Source: Cancer / Oncology News From Medical News Today [2016.07.19]
Phase II trial suggests therapy should be standard of care for patients facing relapsed or treatment-resistant Hodgkin lymphoma.
REVLIMID (lenalidomide) approved by the European Commission for the treatment of relapsed/refractory patients with mantle cell lymphoma
Source: Cancer / Oncology News From Medical News Today [2016.07.18]
Celgene International SaĚ€rl, a wholly owned subsidiary of Celgene Corporation has announced that the European Commission (EC) has approved REVLIMID® (lenalidomide) for the treatment of adult...
Source: MedicineNet Aches, Pain, Fever Specialty [2016.07.14]
Title: Non-Hodgkin's Lymphoma
Category: Diseases and Conditions
Created: 12/31/1997 12:00:00 AM
Last Editorial Review: 7/14/2016 12:00:00 AM
Stage IV Lung Cancer With ALK (Anaplastic Lymphoma Kinase) Rearrangement
Source: MedicineNet Lung Cancer Specialty [2016.07.01]
Title: Stage IV Lung Cancer With ALK (Anaplastic Lymphoma Kinase) Rearrangement
Category: Doctor's & Expert's views on Symptoms
Created: 7/1/2016 12:00:00 AM
Last Editorial Review: 7/1/2016 12:00:00 AM
Mantle Cell Lymphoma (MCL)
Source: MedicineNet Aches, Pain, Fever Specialty [2016.06.29]
Title: Mantle Cell Lymphoma (MCL)
Category: Doctor's & Expert's views on Symptoms
Created: 9/9/2014 12:00:00 AM
Last Editorial Review: 6/29/2016 12:00:00 AM
Published Studies Related to Folotyn (Pralatrexate)
Pralatrexate with vitamin supplementation in patients with previously treated, advanced non-small cell lung cancer: safety and efficacy in a phase 1 trial. [2011.11]
INTRODUCTION: Pralatrexate is an antifolate designed for preferential tumor cell uptake and accumulation and received accelerated Food and Drug Administration approval in relapsed/refractory peripheral T-cell lymphoma. Pralatrexate 135 to 150 mg/m(2) every 2 weeks without vitamin supplementation was active in non-small cell lung cancer (NSCLC) although mucositis was dose limiting. This phase 1 study evaluated the safety of higher pralatrexate doses with vitamin supplementation to minimize toxicities... CONCLUSIONS: Pralatrexate with vitamin supplementation was safely administered to patients with previously treated NSCLC, and durable responses were observed. The recommended starting dose for phase 2 is 190 mg/m(2). A similar safety profile was observed in patients treated at 230 mg/m(2), although a higher serious AE rate was evident. Mucositis remains the dose-limiting toxicity of pralatrexate, and this study failed to demonstrate that vitamin supplementation prevents mucositis and failed to identify clinical predictors of mucositis. Individualized dose-modification strategies and prospective mucositis management will be necessary in future trials.
Pralatrexate: A novel synthetic antifolate for relapsed or refractory peripheral T-cell lymphoma and other potential uses. [2011.09.26]
CONCLUSION: PDX provides clinical benefit to patients with relapsed or refractory PTCL with durable complete and partial responses in patients who had not responded to multiple prior treatment regimens.
Evaluation of the pharmacokinetics, preclinical and clinical efficacy of pralatrexate for the treatment of T-cell lymphoma. [2011.09]
INTRODUCTION: Peripheral T-cell lymphomas (PTCLs) are a heterogeneous group of T-cell neoplasms. Most patients with PTCL have a poor outcome with conventional therapies and are not cured without stem-cell transplantation... The most frequent adverse events in these trials were mucositis, reversible thrombocytopenia and fatigue.
Pralatrexate in patients with relapsed or refractory peripheral T-cell lymphoma: results from the pivotal PROPEL study. [2011.03.20]
PURPOSE: Peripheral T-cell lymphoma (PTCL) is a poor prognosis subtype of non-Hodgkin's lymphoma with no accepted standard of care. This study evaluated the efficacy and tolerability of pralatrexate, a novel antifolate with promising activity... CONCLUSION: To our knowledge, PROPEL (Pralatrexate in Patients with Relapsed or Refractory Peripheral T-Cell Lymphoma) is the largest prospective study conducted in patients with relapsed or refractory PTCL. Pralatrexate induced durable responses in relapsed or refractory PTCL irrespective of age, histologic subtypes, amount of prior therapy, prior methotrexate, and prior autologous stem-cell transplant. These data formed the basis for the US Food and Drug Administration approval of pralatrexate, the first drug approved for this disease.
Single agent and combination studies of pralatrexate and molecular correlates of sensitivity. [2011.01.18]
BACKGROUND: Pralatrexate is a dihydrofolate reductase (DHFR) inhibitor with high affinity for reduced folate carrier 1 (RFC-1) and folylpolyglutamate synthetase (FPGS), resulting in extensive internalization and accumulation in tumour cells. Pralatrexate is approved in the US for the treatment of relapsed or refractory peripheral T-cell lymphoma and is being investigated in various malignancies. Here, we evaluated molecular correlates of sensitivity to pralatrexate and explored combinations with a variety of anticancer agents... CONCLUSION: Pralatrexate was more potent than methotrexate in a panel of solid tumour lines. Our findings support the further clinical development of pralatrexate in combination with certain cytotoxics and targeted therapies, and suggest that RFC-1, FPGS and DHFR may be potential biomarkers of outcome.
Clinical Trials Related to Folotyn (Pralatrexate)
Phase 2, Single Arm, Open Label Study of Folotyn in Combination With Oral Leucovorin to Prevent or Reduce Mucositis in Patients With PTCL [Recruiting]
Phase 1 Study of Fusilev to Prevent or Reduce Mucositis in Patients With Non-Hodgkin's Lymphoma Receiving Folotyn [Withdrawn]
The purpose of this study is determine the optimal dose and schedule of Fusilev to prevent
or reduce Mucositis in patients with Non-Hodgkin's Lymphoma receiving Folotyn treatment.
Phase 1 Study of Fusilev® to Prevent or Reduce Mucositis in Patients With Non-Small Cell Lung Cancer Receiving Folotyn® [Withdrawn]
To determine the optimal dose and schedule of Fusilev to prevent or reduce Folotyn-related
Grade 3 or higher oral mucositis in patients with Non-Small Cell Lung Cancer.
Study of Pralatrexate vs. Erlotinib for Non-Small Cell Lung Cancer After at Least 1 Prior Platinum-based Treatment [Completed]
The purpose of this clinical study is to determine the effectiveness (ability to provide
beneficial treatment of the disease) and safety of pralatrexate compared to erlotinib when
given to non-small cell lung cancer (NSCLC) patients who are current or former cigarette
smokers and who have received at least 1 prior treatment with a platinum drug (cisplatin or
Erlotinib in Combination With Pralatrexate in Advanced Malignancies [Recruiting]
The goal of this clinical research study is to find the highest tolerable dose of the
combination of erlotinib and pralatrexate that can be given to patients with advanced
cancer. The safety of the drug combination will also be studied.
Pralatrexate is designed to block the body's ability to make folic acid, a protein that may
help cancer tissue to develop and spread.
Erlotinib hydrochloride is designed to block proteins that are thought to cause cancer cells
to grow. Erlotinib may help slow the growth of tumors.
Reports of Suspected Folotyn (Pralatrexate) Side Effects
Febrile Neutropenia (5),
Mucosal Inflammation (5),
Disease Progression (4),
Platelet Count Increased (3),
Device Related Infection (3),
Abdominal Pain Upper (3),
Acute Respiratory Distress Syndrome (3),
Stomatitis (3), more >>